Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
NCT03132038
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
98
Enrollment
OTHER
Sponsor class
Conditions
Salivary Gland Carcinoma
Metastatic Cancer
Recurrent Cancer
Interventions
DRUG:
Nivolumab
Sponsor
UNICANCER